IDOGEN.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 Jul 2023 @ 10:26):

Stats
Today's Volume	1.13M
Average Volume	0.00
Market Cap	12.79M
EPS	SEK-0.0727 ( 2023-05-09 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.320
ATR14	SEK0.0520 (43.15%)

Volume Correlation

Long: 0.58 (weak)

Short: 0.25 (neutral)

Signal:(48.38) Neutral

Idogen AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Idogen AB (publ) Correlation - Currency/Commodity

0.12
( neutral )

0.05
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.28
( neutral )

-0.22
( neutral )

Idogen AB (publ) Financials

Annual	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.760

Q1	2023
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.0727

Q4	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.180

Q3	2022
Revenue:	SEK0
Gross Profit:	SEK0 (0.00 %)
EPS:	SEK-0.200

Financial Reports:

No articles found.

Idogen AB (publ)

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.